Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Retatrutide (LY3437943) in High BMI Participants
NCT05959096Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Primary completion
- Jul 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of retatrutide in obesity and Overweight (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity and Maximum Concentration. Started Jul 2023; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT05959096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05959096.